Oruka Therapeutics, Inc. (NASDAQ:ORKA)
| Market Cap | 4.79B+251.5% |
| Revenue (ttm) | 0 |
| Net Income | -132.89M-23.5% |
| EPS | -2.47+45.5% |
| Shares Out | 60.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Aug 29, 2024 |
| Volume | 809,887 |
| Open | 79.01 |
| Previous Close | 80.18 |
| Day's Range | 78.55 - 81.39 |
| 52-Week Range | 21.66 - 115.52 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 144.56(+81.84%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ORKA
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ORKA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ORKA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ORKA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ORKA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ORKA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ORKA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ORKA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $160.10M |
| XBIState Street SPDR S&P Biotech ETF | $135.62M |
| IWMiShares Russell 2000 ETF | $105.49M |
| VXFVanguard Extended Market ETF | $54.53M |
| IWOiShares Russell 2000 Growth ETF | $37.84M |
| IBBiShares Biotechnology ETF | $35.68M |
Estimated from each fund’s disclosed top holdings × AUM
ORKA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ORKA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score